Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 510-516

  Mostert, B ^a   Sieuwerts, A M ^a   Kraan, J ^a   Bolt de Vries, J ^a   van der Spoel, P ^a   van Galen, A ^a   Peeters, D J ^b   Dirix, L Y ^b   Seynaeve, C M ^a   Jager, A ^a   de Jongh, F E ^c   Hamberg, P ^d   Stouthard, J M L ^e,g   Kehrer, D F S ^f   Look, M P ^a   Smid, M ^a   Gratama, J W ^a   Foekens, J A ^a   Martens, J W M ^a   Sleijfer, Stefan ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c IKAZIA HOSPITAL   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e Maasstad Hospital Rotterdam   (Netherlands)

^f IJSSELLAND HOSPITAL   (Netherlands)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Circulating tumor cells; Gene expression; Prediction; Prognosis; RT qPCR

Indexed keywords

MESSENGER RNA; TUMOR MARKER;

ARTICLE; BREAST METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; VISCERAL METASTASIS; ADULT; BELGIUM; BREAST NEOPLASMS; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PROCEDURES; TUMOR EMBOLISM;

ADULT; BELGIUM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84941654093     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu557     Document Type: Article

References (19)

1. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12: R92.
2. Turner NH, Di Leo A. HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev 2013; 39: 947-957.
3. Baldus SE, Schaefer KL, Engers R et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
4. van de Stolpe A, Pantel K, Sleijfer S et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res 2011; 71: 5955-5960.
5. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
6. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
7. Smerage JB, Barlow WE, Hortobagyi GN et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32: 3483-3489.
8. Sieuwerts AM, Kraan J, Bolt-de Vries J et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009; 118: 455-468.
9. Sieuwerts AM, Mostert B, Bolt-de Vries J et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011; 17: 3600-3618.
10. Mostert B, Kraan J, Bolt-de Vries J et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011; 127: 33-41.
11. Sieuwerts AM, Kraan J, Bolt J et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 61-66.
12. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29: 456-463.
13. Gennari A, Conte P, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-1750.
14. Onstenk W, Gratama JW, Foekens JA, Sleijfer S. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev 2013; 39: 691-700.
15. Magbanua MJ, Sosa EV, Roy R et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 2013; 73: 30-40.
16. Chiu CG, Nakamura Y, Chong KK et al. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 2014; 60: 873-885.
17. Swennenhuis JF, Reumers J, Thys K et al. Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. Genome Med 2013; 5: 106.
18. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
19. Peeters DJ, van Dam PJ, Van den Eynden GG et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer 2014; 110: 375-383.